SCHEMBL909795

SCHEMBL909795

CC(C)(c1ccc2c(n1)CCC(C(=O)Nc1ccc(Br)cc1)C2)C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
FAAH O00519 1/20 0.38
LMNA P02545 2/20 0.37
HTT P42858 1/20 0.37
EPHX2 P34913 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA13 Q8N1Q1 1/20 0.36
CA5B Q9Y2D0 1/20 0.36
MAPT P10636 1/20 0.35
FPR2 P25090 1/20 0.35
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL537526 1.00 GHSR (0.39) GHSRMEN1KMT2AL3MBTL1FAAH
SCHEMBL1209845 0.81 TRPV1 (0.53) KMT2ALMNANPC1RAB9ATDP1
SCHEMBL1211712 0.81 TRPV1 (0.53) KMT2ALMNANPC1RAB9ATDP1
SCHEMBL1211511 0.80 TRPV1 (0.48) LMNAEPHX2MAPTNPC1RAB9A
SCHEMBL14781427 0.80 TRPV1 (0.48) LMNAEPHX2MAPTNPC1RAB9A
SCHEMBL909762 0.80 PDK1 (0.36)
SCHEMBL537597 0.80 PDK1 (0.36)
SCHEMBL537517 0.79 RORC (0.35) KMT2AFAAHMAPTTDP1
SCHEMBL1208729 0.78 RORC (0.36) NPC1RAB9ARAF1BRAF
SCHEMBL1210282 0.78 RORC (0.36) NPC1RAB9ARAF1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153651-B2 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same EVOTEC AG (DE) 2012-04-10 US disclosed
EP-2215054-B1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME RENOVIS INC (US) 2011-08-31 EP disclosed
US-20110021514-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME RENOVIS, INC. (US) 2011-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021514-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME TRPV1, TRPA1, TRPV2 GHSR 2949/4885MEN1 4561/4885KMT2A 4331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.